Navigation Links
Scripps research scientists engineer new type of vaccination that provides instant immunity
Date:3/2/2009

The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen. This new method of vaccination could potentially be used to provide instantaneous protection against diseases caused by viruses and bacteria, cancers, and even virulent toxins.

The work is being published in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS) the week of March 2, 2009.

The team, led by Scripps Professor Carlos Barbas, III, Ph.D., tested the vaccination method called covalent immunization on mice with either melanoma or colon cancer.

The scientists injected these mice with chemicals specifically designed to trigger a programmable and "universal" immune reaction. They developed other chemicals, "adapter" molecules," that recognized the specific cancer cells. Once injected into the animal, the adapter molecules self-assembled with the antibodies to create covalent antibody-adapter complexes.

"The antibodies in our vaccine are designed to circulate inertly until they receive instructions from tailor-made small molecules to become active against a specific target," Barbas says. "The advantage of this method is that it opens up the possibility of having antibodies primed and ready to go in the time it takes to receive an injection or swallow a pill. This would apply whether the target is a cancer cell, flu virus, or a toxin like anthrax that soldiers or even civilian populations might have to face during a bioterrorism attack."

Only those mice that received both the vaccine and the adapter compound generated an immediate immune attack on the cancer cells that led to significant inhibition of tumor growth. This is the first time that such a covalent vaccine has been successfully designed and tested typically, antibodies do not bind to chemicals in this covalent fashion.

The current breakthrough builds on work the Barbas laboratory has been engaged in for the past few years on chemically programmed monoclonal antibodies, a new class of therapeutics that the group invented. In this type of therapy, small, cell-targeting molecules and non-targeting catalytic monoclonal antibodies self-assemble to target pathogens. Monoclonal antibodies are produced in the laboratory from a single cloned B-cell the immune system cell that makes antibodies to bind to a specific substance. Three clinical trials are now under way by Pfizer to test the therapeutic effectiveness of this new type of therapy in cancer and diabetes. The antibodies in the antibody-adapter complex are monoclonal antibodies engineered to link themselves to adapter molecules.

The Search for the Ideal Vaccination

The practice of vaccination has been extraordinarily successful in controlling certain diseases, but there are drawbacks. Vaccine development can be an educated guessing game in the case of the flu, for example, scientists must study worldwide outbreak patterns to anticipate which type of flu might strike a particular area. In addition, the most common vaccination strategies use whole proteins, viruses, or other complex immunogens not just the specific part of the macromolecule that is recognized by the immune system to elicit an immune response, which makes for wasted immune activity. Then there is the body's own kinetics the time it takes to mount a disease-relevant immune response to immunogens limits the speed with which immunity can be achieved. Finally, age-related declines in the ability to mount strong immune responses to biological-based vaccines present another challenge to the effectiveness of such vaccines.

Barbas's chemical-based rather than biological based approach to vaccine development addresses many of these challenges.

"Our approach differs from the traditional vaccine approach in the sense that when we design an antibody-adapter compound we know exactly what that compound will react with," Barbas says. "The importance of this is best exemplified with HIV. In current vaccines, many antibodies are generated against HIV, but most are not able to target the active part of the virus."

In the near term, Barbas will apply his covalent vaccination approach to HIV, cancer, and infectious diseases for which no vaccines currently exist. A particular focus will be creating adapter molecules specific to these diseases.

"We believe that chemistry-based vaccine approaches have been underexplored and may provide opportunities to make inroads into intractable areas of vaccinology," Barbas says.

In addition to Barbas, co-authors of the paper, "Instant immunity through chemically programmable vaccination and covalent self-assembly," are Mikhail Popkov (who is first author), Beatriz Gonzalez, and Subhash C. Sinha, all of The Scripps Research Institute.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Scripps Research scientists shed new light on how antibodies fight HIV
2. Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County
3. Scripps research scientists discover chemical triggers for aggression in mice
4. Scripps research scientists find new genetic mutation that halts the development of lupus
5. Scripps scientists find calcium channel blockers help normalize lysosomal storage disease cells
6. Scripps scientists peg wind as the force behind fish booms and busts
7. Scripps research scientists devise approach that stops HIV at earliest stage of infection
8. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
9. Scripps research team wins $4M grant to study effects of chronic marijuana use
10. Scripps Florida scientists develop a process to disrupt hepatitis C virion production
11. Scripps Memorial Hospital Nurses Throw Out CNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 2017 , ... In the Health Care IT campaign, Robert Herjavec discusses health ... if you will be attacked, but when.” However, he and many others involved highlight ... , Improvements in auditing and monitoring have taken security in health care a very ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute ... faculty engaged in or interested in palliative care education and research. The Symposium, ... in North County San Diego on Sept. 28 and 29, 2017, on the campus ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will ... the 2016 National Education Policy Center Bunkum Award. We invite you to enjoy our ... This year’s Bunkum winner is the Center for American Progress (CAP), for its report, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, ... a raffle. Throughout the month of February, patients who visit Hamlin Dental Group will ... a dinner for two at the Cheesecake Factory. , Tickets are available for ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Visiomed, the French leader in medical ... changing the landscape of healthcare with their innovative ... custom-made solutions. Recognizing the rising demand of self-monitoring ... without walls, Visiomed has launched BewellConnect, the most ... professionals that is empowering the lives of patients. ...
(Date:2/23/2017)... , Feb. 23, 2017  Genesis Healthcare Services has ... announcement was made by Bill Monast , President ... and Nathan Feltman , executives with Home ... Services, LLC. This acquisition helps Hospice ... of technology enabled durable medical equipment (DME) solutions for ...
(Date:2/23/2017)...  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device ... for the urology market, will release financial results for ... 2016 before the market open on Thursday, March 9, ... conference call and webcast to discuss its financial results ... 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
Breaking Medicine Technology: